Literature DB >> 12117725

Angiotensin II type 1 and 2 receptors in conduit arteries of normal developing microswine.

Susan P Bagby1, Linda S LeBard, Zaiming Luo, Robert C Speth, Bryan E Ogden, Christopher L Corless.   

Abstract

OBJECTIVE: To identify vascular cells capable of responding to angiotensin II (Ang II) generated in conduit arteries, we examined the Ang II type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R) in the thoracic aorta (TA) and abdominal aorta (AA) and branches in 90-day fetal, 3-week postnatal, and 6-month adult microswine. METHODS AND
RESULTS: By autoradiography ((125)I-[Sar(1)Ile(8)]-Ang II with or without AT1R- or AT2R-selective analogues or (125)I-CGP 42112), there were striking rostrocaudal differences in (1) AT2R binding at all ages (prominent in AA wall and branches, sparse in TA wall and branches) and (2) a non-AT2R binding site for CGP 42112 (consistently evident in postnatal TA and branches but absent in AA and branches). Furthermore, patterns of AT2R distribution in infradiaphragmatic arteries were developmentally distinct. In fetal AAs, high-density AT2Rs occupied the inner 60% of the medial-endothelial wall. In postnatal AAs, AT2Rs were sparse in the medial-endothelial wall but prominent in a circumferential smooth muscle alpha-actin-negative cell layer at the medial-adventitial border, occupying approximately 20% to 25% of the AA cross-sectional area. AT1R density in the TA and AA medial-endothelial wall increased with age, whereas AT2R density decreased after birth.
CONCLUSIONS: A novel AT2R-positive cell layer confined to postnatal infradiaphragmatic arteries physically links adventitial and medial layers, appears optimally positioned to transduce AT2R-dependent functions of local Ang II, and suggests that adventitial Ang II may elicit regionally distinct vascular responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117725     DOI: 10.1161/01.atv.0000022382.61262.3e

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Functional role of sodium glucose transporter in high glucose-mediated angiotensin type 1 receptor downregulation in human proximal tubule cells.

Authors:  Rekha Yesudas; Russell Snyder; Thomas Abbruscato; Thomas Thekkumkara
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

2.  Systemic and renal hemodynamic effects of the AT1 receptor antagonist, ZD 7155, and the AT2 receptor antagonist, PD 123319, in conscious lambs.

Authors:  Mona L Chappellaz; Francine G Smith
Journal:  Pflugers Arch       Date:  2006-10-19       Impact factor: 3.657

Review 3.  Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.

Authors:  Douglas M Bennion; Emily Haltigan; Robert W Regenhardt; U Muscha Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

4.  Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation.

Authors:  Jeong-A Kim; Hyun-Ju Jang; Luis A Martinez-Lemus; James R Sowers
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-25       Impact factor: 4.310

5.  Modeling of the renal kinetics of the AT1 receptor specific PET radioligand [11C]KR31173.

Authors:  Nedim C M Gulaldi; Jinsong Xia; Tao Feng; Kelvin Hong; William B Mathews; Dawn Ruben; Ihab R Kamel; Benjamin M W Tsui; Zsolt Szabo
Journal:  Biomed Res Int       Date:  2013-09-08       Impact factor: 3.411

6.  Angiotensin receptors modulate the renal hemodynamic effects of nitric oxide in conscious newborn lambs.

Authors:  Angela E Vinturache; Francine G Smith
Journal:  Physiol Rep       Date:  2014-05-28

7.  Changes in Angiotensin Receptor Distribution and in Aortic Morphology Are Associated with Blood Pressure Control in Aged Metabolic Syndrome Rats.

Authors:  Verónica Guarner-Lans; Elizabeth Soria-Castro; Rocío Torrico-Lavayen; Araceli Patrón-Soberano; Karla G Carvajal-Aguilera; Vicente Castrejón-Tellez; María Esther Rubio-Ruiz
Journal:  Int J Hypertens       Date:  2016-05-17       Impact factor: 2.420

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.